Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TSSK6-activating co-chaperone protein (TSACC) is a cytoplasmic protein that serves as a co-chaperone, directly binding to both HSP70 and TSSK6, and associates with HSP90[4][1][3]. TSACC selectively facilitates HSP90-mediated activation of the testis-specific serine/threonine kinase TSSK6 (also known as SSTK), playing a key role in the stabilization, folding, and activation of TSSK6 during spermiogenesis[1][2][4]. This function is thought to be specific for post-meiotic male germ cells, where correct activation of TSSK6 is essential for male fertility in mammals[1]. There is no clear evidence that TSACC serves as a direct therapeutic target, nor is it currently associated with any known drug interactions, biomarker status, or specific safety risks.
Not applicable; no drugs currently target TSACC
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TSSK6-activating co-chaperone protein (TSACC).